The chain faced shortfalls in foot traffic due to significant changes to the workforce and consumption patterns in the ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be launch-ready by the end of the year if approved. Compass recently held a ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

Kallyope, a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally, announced ...

Compass Pathways has entered its seventh U.S. strategic collaboration with Radial Health. Radial Health operates in five ...

Cardinal Health plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaborati ...

Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to ...

We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, CEO ...